Strata Oncology
Strata Oncology is a precision oncology company in Ann Arbor, United States, developing algorithmic biomarkers for antibody-drug conjugates and immunotherapy.
Last updated September 16, 2026
AI crawler reads
2requests
1companies- Anthropic2
- Profile
- 2
- Controversies
- 0
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
Strata Oncology is a precision oncology company based in Ann Arbor, United States. Its mission is to accelerate the impact of precision medicine for patients with cancer. The company develops advanced algorithmic biomarkers for antibody-drug conjugates (ADCs) and immunotherapy, including Antibody-drug Conjugate Treatment Response Scores and an Immunotherapy Response Score. Dan Rhodes, PhD serves as Co-Founder & CEO, and Scott Tomlins, MD, PhD as Co-founder & Chief Medical Officer.
History
Strata Oncology is a company in Ann Arbor, United States. It describes itself as a next-generation precision oncology company enabling smarter cancer treatment so that every patient gets their best possible therapy. Its mission is to accelerate the impact of precision medicine for patients with cancer. The company develops advanced algorithmic biomarkers for antibody-drug conjugates and immunotherapy.
Products and positioning
Precision oncology; advanced algorithmic biomarkers for antibody-drug conjugates and immunotherapy
Antibody-drug Conjugate Treatment Response Scores
Predictive biomarkers for benefit from a variety of approved and investigational antibody-drug conjugates (ADCs); based on a proprietary calculation method of three components including ADC target expression.
Immunotherapy Response Score
A pan-solid tumor predictive diagnostic tool for anti-PD-1/PD-L1 monotherapy benefit. This biomarker algorithm combines tumor mutation burden (TMB) with quantitative expression of PD-L1, PD-1, ADAM12 and TOP2A.
Recent events
- Unconfirmed
Reported
Strata Oncology raises $90 million in Series C funding[4]
Strata Oncology announced that it had raised $90 million in a Series C financing round. The company said the proceeds would support development of its personalized minimal residual disease assay and RNA-based treatment selection tests.
Reported
Strata Oncology launches Strata Assistant for Epic[5]
Strata Oncology announced the launch of Strata Assistant for Epic, an app integrated with the Epic electronic medical record system to streamline StrataNGS test submission. Kettering Health Network was its first fully integrated user.
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/strata-oncology-united-states · Editorial policy · How profiles are compiled